Sylvia Miescher

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 40(Granted Patents)

Company Filing History:

University of Washington

patents

7. 1 out of 517

Beth Israel Deaconess Medical Center, Inc.

where one patent can have more than one assignee

Years Active: 2006-2021

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10973891 - Treatment and prevention of remote ischemia-reperfusion injury (2021-04-13),

2. 10286047 - Treatment and prevention of remote ischemia-reperfusion injury (2019-05-14),

3. 10221233 - Compositions comprising secretory-like immunoglobulins (2019-03-05),

4. 9932392 - Prevention of infection (2018-04-03),

5. 9546209 - Treatment of mucositis with immunoglobulin (2017-01-17),

6. 9522184 - CD89 activation in therapy (2016-12-20),

7. 8632773 - Antibody composition with altered Fab sialylation (2014-01-21),

8. 7887797 - Immunoglobulin fractions (2011-02-15),

9. 7429647 - Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use (2008-09-30),

10. 7399471 - Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use (2008-07-15),

11. 7038020 - Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use (2006-05-02),

Title: Celebrating Sylvia Miescher: Innovator in Medical Treatments

Introduction: Sylvia Miescher, an accomplished inventor based in Bern, Switzerland, has made significant strides in the realm of medical innovations. With a portfolio of 11 patents, her groundbreaking research is focused on the treatment and prevention of remote ischemia-reperfusion injury, showcasing her dedication to advancing healthcare solutions.

Latest Patents: Among her notable patents is a recent invention relating to the use of a contact activation system inhibitor, preferably C1INH. This invention is directed towards the treatment and prevention of remote ischemia-reperfusion injury (IRI) and entails the administration of the contact activation system inhibitor to an individual. This innovation has the potential to significantly improve patient outcomes in those suffering from this serious condition.

Career Highlights: Sylvia Miescher has built an impressive career marked by her contributions to groundbreaking medical technologies. Her work has been instrumental in developing treatments that address critical health challenges, particularly in the field of ischemia-reperfusion injuries.

Collaborations: Collaboration has been key to Sylvia’s achievements, as she has worked alongside esteemed colleagues such as Andreas Morell and Martin Imboden. Their collective efforts have contributed to advancing the state of medical treatments through innovative research and development.

Conclusion: Sylvia Miescher is a trailblazer in medical innovation, with a strong focus on improving treatments for conditions such as remote ischemia-reperfusion injury. Her 11 patents reflect her commitment to enhancing healthcare outcomes through her inventive solutions, marking her as a prominent figure in the world of medical inventions.

This text is generated by artificial intelligence and may not be accurate.